Severe Ureaplasma urealyticum infection in a patient with ocrelizumab-induced hypogammaglobulinaemia

BMJ Case Rep. 2023 Sep 26;16(9):e256029. doi: 10.1136/bcr-2023-256029.

Abstract

Infections caused by Ureaplasma urealyticum in immune-competent people are typically simple and uncomplicated. However, in cases of immunosuppression, severe disseminated infections can occur.This case report describes the case of a severe, disseminated infection caused by U. urealyticum in a young female with unacknowledged humoral immunosuppression due to treatment with ocrelizumab for multiple sclerosis.The patient was admitted due to a recurrent episode of a tubo-ovarian abscess. Throughout the following 2 months of hospitalisation, treatment with several types of antibiotics and the placement of various drains led to no improvement. As extensive investigations indicated hypogammaglobulinaemia, U. urealyticum was suspected, and tests came back positive. Treatment with doxycycline and moxifloxacin led to a full recovery.This demonstrates how humoral immunosuppression is a risk factor for severe disseminated infections and how these may be avoided through monitoring of immunoglobulin levels in patients treated with ocrelizumab.

Keywords: Multiple sclerosis; Pelvic inflammatory disease; Unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Agammaglobulinemia* / chemically induced
  • Agammaglobulinemia* / drug therapy
  • Anti-Bacterial Agents / adverse effects
  • Doxycycline / adverse effects
  • Female
  • Humans
  • Ureaplasma Infections* / diagnosis
  • Ureaplasma Infections* / drug therapy
  • Ureaplasma urealyticum

Substances

  • ocrelizumab
  • Anti-Bacterial Agents
  • Doxycycline